Last Updated: October 29, 2026

Details for Patent: 7,601,746


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 7,601,746
Title:Compounds exhibiting thrombopoietin receptor agonism
Abstract:A compound represented by the general formula (I): wherein R1 is a hydrogen atom, a halogen atom, or the like; R2, R3, and R4 are each independently a hydrogen atom, a halogen atom, C1-C15 alkyl optionally substituted with one or more C1-C12 alkyloxy or the like, or the like; R5 is a hydrogen atom or the like; R6 and R7 are a hydrogen atom or the like; R8 is C1-C3 alkyl or the like; R9 is a hydrogen atom or the like), a prodrug, a pharmaceutically acceptable salt, or solvate thereof.
Inventor(s):Masami Takayama, Yutaka Yoshida
Assignee: Eddingpharm Hong Kong Co Ltd
Application Number:US10/567,993
Patent Claim Types:
see list of patent claims
Use; Composition;

Drugs Protected by US Patent 7,601,746

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 7,601,746

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Japan2003-292080Aug 12, 2003
PCT Information
PCT FiledAugust 10, 2004PCT Application Number:PCT/JP2004/011453
PCT Publication Date:February 17, 2005PCT Publication Number: WO2005/014561

International Family Members for US Patent 7,601,746

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia 2004263442 ⤷  Start Trial
Canada 2535511 ⤷  Start Trial
China 102796058 ⤷  Start Trial
China 103130739 ⤷  Start Trial
China 1863783 ⤷  Start Trial
European Patent Office 1655291 ⤷  Start Trial
Spain 2599529 ⤷  Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.